EntryPoint Capital LLC Makes New Investment in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• EntryPoint Capital LLC invested approximately $186,000 in Eyepoint Pharmaceuticals, acquiring 34,324 shares of the company's stock in the first quarter.
• Eyepoint Pharmaceuticals reported a loss of $0.85 earnings per share for the last quarter, missing the consensus estimate, with a negative net margin of 337.93%.
• Analyst ratings show a consensus "Buy" rating for Eyepoint Pharmaceuticals, with an average target price of $25.38, despite recent price target adjustments from several firms.

EntryPoint Capital LLC purchased a new position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,324 shares of the company's stock, valued at approximately $186,000.

Several other hedge funds also recently modified their holdings of the company. Bank of America Corp DE increased its holdings in Eyepoint Pharmaceuticals by 28.8% in the 4th quarter. Bank of America Corp DE now owns 648,030 shares of the company's stock worth $4,828,000 after purchasing an additional 145,065 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Eyepoint Pharmaceuticals by 70.7% in the fourth quarter. ProShare Advisors LLC now owns 21,679 shares of the company's stock valued at $162,000 after buying an additional 8,981 shares during the period. Millennium Management LLC bought a new position in Eyepoint Pharmaceuticals in the 4th quarter valued at approximately $3,324,000. California State Teachers Retirement System boosted its position in Eyepoint Pharmaceuticals by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after buying an additional 1,797 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Eyepoint Pharmaceuticals by 38.3% during the 4th quarter. MetLife Investment Management LLC now owns 40,502 shares of the company's stock worth $302,000 after acquiring an additional 11,217 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT traded down $0.03 during mid-day trading on Friday, hitting $11.57. The company had a trading volume of 491,715 shares, compared to its average volume of 703,188. Eyepoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $13.98. The firm has a fifty day moving average price of $10.45 and a 200 day moving average price of $7.86. The company has a market capitalization of $797.52 million, a PE ratio of -4.32 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $6.82 million. Research analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on EYPT shares. Royal Bank Of Canada started coverage on shares of Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price target on the stock. Chardan Capital reiterated a "buy" rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. HC Wainwright raised their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Finally, Mizuho cut their price objective on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $26.86.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.